
WilmerHale Counsels Investors Abingworth Bioventures and Atlas Venture in IFM Therapeutics Acquisition by Bristol-Myers Squibb

AUGUST 14, 2017

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders. IFM is a privately held biopharmaceutical company based in Boston, Massachusetts, and financed by Abingworth Bioventures and Atlas Venture.

The WilmerHale deal team representing Atlas Venture and Abingworth Bioventures included [Stuart Falber](#), [Bill Caporizzo](#), [Steve Barrett](#) and [Jeff Hermanson](#).

Read [IFM's press release](#) for more information.